Infectious Disease Book

http://www.fpnotebook.com/

Penicillin Resistant Pneumococcus

Aka: Penicillin Resistant Pneumococcus, PRP, Streptococcus Pneumoniae Antibiotic Resistance, Drug Resistant Pneumococci, DRSP
  1. Epidemiology
    1. Very serious problem
      1. Pneumococcus infection is common
      2. Otitis Media
      3. Meningitis
    2. Treatment failures common especially in Meningitis
    3. Hot spots of resistance
      1. International
        1. Spain
        2. Hungary
        3. South Africa
      2. United States
        1. Dallas
        2. Memphis
        3. Kansas City
        4. Oklahoma City
    4. High Risk Groups (New York, 1995, n=282)
      1. Children under age 4 (7.5 cases per 100,000)
      2. Children under age 1 (30.3 cases per 100,000)
      3. Adults with Human Immunodeficiency Virus (HIV)
      4. Reference
        1. (1997) MMWR Morb Mortal Wkly Rep, 46:297-9 [PubMed]
    5. Day Care Prevalence (multiple U.S. state evaluation)
      1. Nasopharyngeal and middle ear swab: 22-29% PRP
    6. Hospital Prevalence (Minneapolis, MN)
      1. Community Hospitals: 15-22% PRP
      2. Tertiary Care Hospital: 50% PRP
    7. Streptococcus Pneumoniae Resistance Rates (2003)
      1. Highest resistance (19-30%)
        1. Penicillin (21%)
        2. Cephalosporins: Cefprozil, Cefuroxime (23-25%)
        3. Macrolides: All are high resistance (23-28%)
        4. Tetracycline (19%)
        5. Trimethoprim-Sulfamethoxazole (30%)
      2. Lowest resistance rates (<10%)
        1. Amoxicillin-Clavulanate (4%)
        2. Cefepime (<1%)
        3. Ceftriaxone (2%)
        4. Fluoroquinolones: Levaquin, Avelox (<1%)
        5. Clindamycin (9%)
        6. Vancomycin (0%)
      3. References
        1. Jones (2003) Diagn Microbiol Infect Dis 46:77-80 [PubMed]
  2. Risk Factors
    1. Age over 65 years (Odds Ratio 3.8)
    2. Within last 3 months, beta-lactam antibiotic - Penicillins, Cephalosporins, carbapenems, and monobactams (Odds Ratio 2.8)
    3. Alcohol Abuse (Odds Ratio 5.2)
    4. Immunosuppression
    5. Multiple comorbid medical conditions
    6. Exposure to day-care attending children
    7. Reference
      1. Fraboni (2012) Board Review Express, San Jose
  3. Management: Pneumonia or Sepsis
    1. Intermediate Resistance
      1. Higher Penicillin dosage: 150k-250k U/kg/day
    2. High Resistance
      1. Three drug Combination regimen
        1. Vancomycin (40 mg/kg/day) and
        2. Imipenem and
        3. Rifampin
      2. Two drug combination regimen
        1. Vancomycin
        2. Third generation Cephalosporin (if not resistant)
  4. Management: Meningitis
    1. Intermediate Resistance
      1. Vancomycin (60 mg/kg/day) and
      2. Imipenem
    2. High resistance
      1. Vancomycin (60 mg/kg/day) and
      2. Rifampin and
      3. Imipenem
    3. Follow-Up Spinal Tap in 24 hours
  5. Management: Otitis Media
    1. Intermediate Resistance
      1. Amoxicillin (75 mg/kg/d)
      2. Clindamycin
        1. No coverage for HaemophilusInfluenzae
        2. No coverage for Moraxella catarrhalis
      3. Cefuroxime
      4. Cefprozil
      5. Cefpodoxime
    2. High Resistance
      1. Base on Tympanocentesis culture
  6. Prevention
    1. Pneumococcal Vaccine
      1. Public Health may add to 2 year old Immunizations
      2. Would create herd immunity to some pneumococcus

Platelet rich plasma (C0370220)

Definition (NCI) A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to concentrate the amount of platelets.
Definition (NCI_CDISC) A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to concentrate the amount of platelets. (NCI)
Definition (MSH) A preparation consisting of PLATELETS concentrated in a limited volume of PLASMA. This is used in various surgical tissue regeneration procedures where the GROWTH FACTORS in the platelets enhance wound healing and regeneration.
Concepts Body Substance (T031)
MSH D053657
SnomedCT 116203006
HL7 PRP
LNC LP7506-1, MTHU003693
English Plasma, Platelet-Rich, Platelet Rich Plasma, Platelet-Rich Plasma, plasma rich platelet, platelet rich plasma, plasma platelet rich, plasma platelets rich, PLATELET RICH PLASMA, PRP, Platelet-rich Plasma, Platelet rich plasma (substance), Platelet rich plasma
Portuguese Plasma Rico em Plaquetas
Spanish Plasma Rico en Plaquetas, plasma rico en plaquetas (sustancia), plasma rico en plaquetas
Russian ТРОМБОЦИТ-НАСЫЩЕННАЯ ПЛАЗМА, ТРОМБОЦИТ-ОБОГАЩЕННАЯ ПЛАЗМА, TROMBOTSIT-NASYSHCHENNAIA PLAZMA, TROMBOTSIT-OBOGASHCHENNAIA PLAZMA
Italian Plasma ricco di piastrine
German Thrombozytenreiches Plasma, Blutplättchenreiches Plasma
French Plasma riche en plaquettes, PRP (Plasma Riche en Plaquettes), Plasma enrichi en plaquettes
Swedish Trombocytrikplasma
Finnish Verihiutaletiiviste
Czech plazma bohatá na destičky
Polish Osocze bogatopłytkowe
Croatian PLAZMA BOGATA TROMBOCITIMA
Norwegian Trombocyttkonsentrater, Blodplaterik plasma
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree